A cascade involving edema, an inflammatory response, ROS/reactive nitrogen species (RNS) production, glutamate-mediated toxic effects, neuronal apoptosis, ferroptosis, and glial scarring occurs after SCI [31,32,33]
Fridays approval of Eli Lillys weight loss Zepbound (tirzepatide) to treat moderate to severe obstructive sleep apnea in adults with obesity solidified an expansionist precedent first set by Lillys main GLP-1 competitor, Novo Nordisk
Food and Drug Administration: (May 2022) Approved as adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus (November 2023) Approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (December 2024) Expanded indication for moderate-to-severe obstructive sleep apnea in adults with obesity Classified as first-in-class dual GIP/GLP-1 receptor agonist Not approved for type 1 diabetes mellitus or as monotherapy in patients with history of pancreatitis International Regulatory Approvals GLP2 has received regulatory approval in multiple jurisdictions: European Union (September 2022) Type 2 diabetes treatment United Kingdom (November 2023) Expanded to include weight management Canada (November 2022) Type 2 diabetes indication Australia (December 2022) Type 2 diabetes treatment Additional regulatory reviews ongoing in other countries Warnings and Contraindications Important safety considerations include: Boxed Warning for thyroid C-cell tumor risk (based on rodent studies
Ponadto BPC 157 moe rwnie zmniejsza objawy stanw zapalnych ukadu nerwowego i chorb neurodegeneracyjnych, takich jak choroba Parkinsona, uszkodzenie rdzenia krgowego itp
